Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909452 · ClinicalTrials.gov registry record · Phase 1
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
A Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02909452 is a Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 30 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02909452, a Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Entinostat
Study Locations (1)
Texas
- The START Center for Cancer Care - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2021-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02909452
The ClinicalTrials.gov registry entry for NCT02909452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02909452 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02909452 about?
NCT02909452 is a clinical study titled "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy
What is the current status of trial NCT02909452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-09-20. Estimated completion is 2021-02-09.
What conditions does trial NCT02909452 study?
This clinical trial studies the following conditions: Neoplasms, Carcinoma, Non-Small Cell Lung, Lung Neoplasms, Neoplasms by Histologic Type, Thoracic Neoplasms.
What interventions are being tested in trial NCT02909452?
The interventions under investigation include: Pembrolizumab (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT02909452?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02909452 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.